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Abstract
Treatments of critical size bone defects represent a clinical challenge. Gold standard therapy
includes autogenous bone graft and alloplastic materials. However, restricted graft availability,
pain, and morbidity limit this therapy. A promising alternative presents tissue engineering with
mesenchymal stem cells derived from the adipose tissue, the so-called adipose-derived stem cells
(ASCs). These cells can be obtained easily and in high numbers. Nevertheless, ASCs consist of
a heterogeneous population of cells. Hence, it is likely that specific subpopulations with a higher
propensity for osteogenic di↵erentiation exist. This Doctoral Thesis dissects the heterogeneity
within human ASCs to identify subpopulations more prone to osteogenic di↵erentiation. We
performed in vitro osteogenic di↵erentiation using ASCs derived from 20 patients. Alizarin
red staining and RTQ-PCR showed considerable di↵erences. The CyTOF technology allowed
analysis on cell by cell level. We found that the ASC lines from di↵erent patients contained
several subpopulations, one of them was identified to be more abundant in good osteogenic
di↵erentiating lines.
In conclusion, di↵erences between the ASC lines were verified and correlate with the clinical
outcomes observed. Thus, identification of the subpopulation with high osteogenic potential
could improve therapy of fractures and predict clinical outcomes.
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Zusammenfassung
Die Behandlung von Knochendefekten kritischer Gro¨sse stellt eine klinische Herausforderung dar.
Die Goldstandardtherapie umfasst autogenes Knochentransplantat kombiniert mit alloplastis-
chen Materialien. Nachteile dieser Therapie sind eingeschra¨nkte Verfu¨gbarkeit des Transplants,
Schmerzen und Morbidita¨t. Ein vielversprechender Ansatz stellt das Tissue Engineering mit
mesenchymalen, adipo¨sen Stammstellen (ASCs) dar. Letztere sind leicht und in grosser Menge
gewinnbar. ASCs sind jedoch sehr heterogen, daher ist anzunehmen, dass sie aus mehreren
Subpopulationen zusammengesetzt sind. Diese Dissertation analysiert die Heterogenita¨t men-
schlicher ASCs mit dem Ziel, spezifische Subpopulationen mit hohem Potenzial zur Knochendif-
ferenzierung zu identifizieren. Wir fu¨hrten eine in vitro osteogene Di↵erenzierung mit ASCs von
20 Patienten durch. Alizarin Fa¨rungen und RTQ-PCR zeigten erhebliche Unterschiede zwischen
den Patienten. CyTOF ermo¨glichte eine Analyse auf Einzellzellebene, wodurch besta¨tigt wurde,
dass ASCs aus mehreren Subpopulationen bestanden. Eine spezifische Subpopulation wurde
ha¨ufiger in Patienten mit guter Knochenheilung identifiziert.
Zusammengefasst konnten Unterschiede zwischen ASCs verschiedener Patienten verifiziert
und mit den verschiedenen Heilungsverla¨ufen korreliert werden. Eine Identifizierung der Sub-
population mit starkem Knochendi↵erenzierungspotential ko¨nnte die Therapie von Frakturen
verbessern und klinische Verla¨ufe vorhersagen.
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AP alkaline phosphatase
AML acute myeloid leukaemia
ASCs adipose-derived mesenchymal stem cells
BMSCs bone marrow stem cells
CD clusters of di↵erentiation
CSB cell staining bu↵er
CyTOF cytometry by time-of-flight
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HLA-DR human leucocyte-DR
hMSCs human mesenchymal stem cells
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ISCT International Society for Cellular Therapy
MSCs mesenchymal stem cells
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PLGA poly-lactic-co-glycolic acid
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RTQ-PCR real-time quantitative PCR
SPADE spanning-tree progression of density-normalized events
SVF stromal vascular fraction
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TNF-↵ tumour recrosis factor-alpha
VEGF vascular endothelial growth factor
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1 Introduction
1.1 Bone characteristics
Bone is a highly specialized tissue forming the fundamental framework of the human body.
Osseous tissue not only has the function of mechanical support, but it is also responsible for
several biological functions and possesses the unique characteristic of self-healing [1]. Through
its hardness and rigidity, bone protects vital organs and also provides onsets for muscles enabling
movements [2]. Bones take part in biological processes such as hematopoietic cell formation in the
bone marrow, mineral homeostasis, and provide a reservoir for growth factors and cytokines [1, 3].
Furthermore, bone constantly undergoes remodelling in order preserve strength by replacing old
bone and also to adjust to changing biomechanical forces such as overloading, growth, disuse
or the time after a fracture’s repair. The remodelling process is regulated through cytokines,
hormones, and chemokines [1, 2].
As already mentioned, bone has the extraordinary property to fully regenerate without scar-
ring. Nevertheless, in some cases bone healing disorders may occur. Reasons for failure of
fracture-healing include large bone defects, pathological fractures, or negative influences such as
insu cient blood supply, systemic diseases, or infection. All these reasons can lead to delayed-
or even non-union of a fracture’s site [4]. Skeletal defects occur following diseases, trauma, con-
genital anomalies, cancer resection, or hereditary defects. The treatment and repair of such
defects, especially the so called ”critical size bone defects”, where bone loss is so gravely that it
does not heal over time, represent a serious clinical challenge for re-constructive and orthopaedic
surgery [5, 6]. Current treatments include bone substitutes from autogenous, xenogeneic as well
as prosthetic materials. The gold standard approach for large bone reconstruction is considered
to be autogenous bone grafts in combination with alloplastic materials. Normally, bone graft is
obtained out of the iliac crest’s spongiosa [4, 5]. However, the supply of autogenous bone graft
is restricted due to limited availability, morbidity, and severe donor site pain. In contrast to
autogenous bone grafts, allografts and xenografts bear the risks of infection, immune rejection,
bone resorption, disease transmission, and diminished graft incorporation. Besides, these kind
of grafts lack of osteogenic properties. What is more, xenogeneic substitutes have the risk of
transfer of zoonotic diseases [5, 6]. To this end, also inorganic and alloplastic materials, for
example ceramics or hydroxy-apatite, can serve as bone substitutes. Disadvantages like contour
irregularities, infection, and structural failure can come along using these materials [6].
In general, no synthetic or natural material provides yet all the needs for bone regeneration but
the patient’s own bone. As the latter has restricted availability, improved therapeutic approaches
are urgently needed [7]. The novel approach of tissue engineering raises a promising alternative
as it would avoid current drawbacks in the treatments of critical size bone defects. Recently,
a cellular-based approach was investigated by combining sca↵olds with mesenchymal stem cells
(MSCs) in order to achieve better healing in bone fractures [5].
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1.2 Mesenchymal stem cells
Mesenchymal stem cells are defined by their occurrence in adult tissue, their specific surface
antigen expression, and their multipotency [8, 9]. Human MSCs (hMSCs) were originally isolated
from bone marrow [10]. In the meantime, hMSCs are being isolated not only from a variety of
adult tissues, for example adipose tissue [11] or synovial fluid [12], but also from foetal tissue
like the Wharton’s jelly [8]. Moreover, MSCs show expression of a specific pattern of surface
markers. To be able to identify MSCs, the International Society for Cellular Therapy (ISCT)
has specified three minimal criteria [9]:
1. Plastic adherence when maintained in standard cell culture.
2. Expression of specific clusters of di↵erentiation (CDs): positive for CD105, CD73, and
CD90 but no expression for CD45, CD34, CD14 or CD11b, CD79 or CD19, and human
leucocyte-DR (HLA-DR).
3. MSCs must be able to di↵erentiate into osteoblasts, adipocytes, and chondroblasts.
Based on the first criterion, as an example, MSCs can be separated from freshly isolated cells
of fat tissue, the so called stromal vascular fraction [13]. Another feature of MSCs represents
their multipotency, enabling di↵erentiation into the mesodermal cell lineages such as osteoblasts
[14], chondrocytes [15], and adipocytes [16]. By now, not only di↵erentiation into mesodermal
tissue lineages, but also the capacity of di↵erentiation into ectodermal tissue (for example skin,
[17]) and endodermal tissue (for instance neural cells [18]) has been reported. Overall, MSCs
are of great interest for cell therapy, regenerative medicine, and tissue repair. In contrast to
embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), MSCs are e↵ortlessly
accessible, expandable in vitro, show exceptional genomic stability and present negligible ethical
issues. Furthermore, MSCs are capable of multilineage potential, influence secretion of anti-
inflammatory molecules and play a role in immunomodulation. These reasons are auspicious for
treatment methods of chronic diseases. To sum up, MSCs are of paramount interest for clinical
research. Recently, tissue engineering with MSCs has been studied using natural and synthetic
biomaterials carrying stem cells as a therapeutic approach. Especially in orthopaedics, this
strategy might lead to a significant improvement of current treatments. Not only the possibility
of obtaining MSCs from various weaves, but also the use of a patients’ very own cells declines
the risk of immune-rejection [19].
Adipose-derived mesenchymal stem cells (ASCs) in particular represent an auspicious source
for application in regenerative medicine. ASCs can be easily gained by lipoaspiration, a minimally
invasive surgical technique providing a satisfactory quantity of cells [20]. Through their high
proliferative rate, ASCs can subsequently be long-term expanded in vitro. Apart from their
straightforward handling in cell culture, ASCs possess a great di↵erentiation potential and a
good genetic stability. On the other hand, stem cells obtained from the bone marrow (BMSCs)
are used as a standard in research and in the clinical setting so far. These cells, however, have
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many disadvantages, such as cell extraction which can only be performed by an invasive, quite
painful procedure connected to a high risk of infection [21]. Furthermore, the isolated MSCs are
more numerous in the adipose tissue than in the bone marrow [22]. Overall, ASCs show great
potential for regenerative medicine due to their easy access by a low-risk procedure, their large
amount of collected cells, and their e↵ortless maintenance in cell culture.
MSCs consist of a heterogeneous mixture of di↵erent cells, which is mirrored in their pro-
tein expression, morphology, and di↵erentiation potentials [23]. Despite this fact, all these cells
meet the above-mentioned criteria of the ISCT [9]. Multiple studies reported single-cell derived
colonies obtained from human MSCs enclose at least three di↵erent morphologies of stem and
progenitor cells (reviewed in [23, 24]). Besides, not only numerous proteins are expressed on vary-
ing levels, but it is also suggested that specific stem cell subpopulations possessing a determined
di↵erentiation lineage subsist within a population of MSCs [23].
For instance, in one study ASCs were obtained from thirty humans and were then di↵eren-
tiated into endothelial cells and osteoblasts [25]. All cells had the ability to di↵erentiate into
those two lineages but were di↵erently successful suggesting the existence of unalike cell pop-
ulations among the donors. From these observations, it follows that extracting a particular
subpopulation of ASCs more capable of di↵erentiating towards a tissue of interest presents a
favourable approach for regenerative medicine. Therefore, it is fundamental to further subdi-
vide MSCs/ASCs and analyse more closely their di↵erentiation potential [23]. What is more,
multiple studies have reported that in general MSCs obtained from various sources express a
great variety of markers (Tab. 1, [23]). For example, CD146 was positively expressed in BMSCs
([26, 27]), but was negative in hASCs [19]. Also, CD271 was found in ASCs but its expression
lacked in other studies [19]. Another example is STRO-1, which was found in BMSCs but not in
hASCs [28]. Clearly, a great variety of markers is found in literature (Tab. 1), and therefore, no
exhaustive list can be proposed. Dissecting the heterogeneity of MSCs is essential for stem cell
based methodologies as well as for better comprehension of biological behaviors [23]. In order
to investigate this objective, the innovative technology of cytometry by time-of-flight o↵ered a
suitable approach.
1.3 Mass cytometry
Cytometry by time-of-flight (CyTOF), also known as mass cytometry, is an innovative break-
through capable of real-time analysis of individual cells. Up to now, flow cytometry fluorescence-
activated cell soring (FACS) was commonly used for single cell measurements for scientific pur-
poses. With this method, cells previously stained with fluorescent-tagged antibodies are guided
one at a time through laser beams consisting of di↵erent wavelengths. The fluorescent light
of each cell is then converted into an electrical signal allowing profiling of subpopulations due
to their expression and also quantification of their signals. However, as the spectral overlap of
the fluorophores limits the amount of parameters that can be analysed simultaneously, FACS
can only be operated with up to 18 protein markers. Cytometry by time-of-flight on the other
10
Table 1: Selected markers for mesenchymal stem cells.
Markers Synonyms Function Cellular expression Papers
MSC positive markers (from the ISCT)
CD105 Endoglin Angiogenesis; Modulation of cellular response to TGF beta
1
MSCs, endothelial cells, erythroid precursors, activated
monocytes and makrophages
[9]
CD90 Thymocyte di↵erentiation antigen 1 (THY1) Costimulation of lymphocytes; cell adhesion MSCs, hematopoietic cells, neuronal cells, fibroblasts, stro-
mal cells, activated endothelial cells
[9]
CD73 5-nucleotidase, NT5E An ecto-5-prime-nucleotidase hydrolyzing extracellular nu-
cleotides into membrane permeable nucleosides
MSCs, T- and B-cell subsets, epithelial and endothelial cells,
dendritic reticulum cells
[9]
MSC negative markers (defined from the ISCT)
CD45 Lymphocyte common antigen Regulation of T- and B-cell antigen receptor signaling; reg-
ulation of cell growth and di↵erentiation
Hematopoietic cells (not platelets and erythrocytes) [9]
CD14 LPS-Receptor Receptor for LPS and LBP Monocytes, macrophages, Langerhans cells, granulocytes [9]
CD19 B-lymphocyte surface antigen B4, T-cell surface antigen
Leu-12
Regulation of B-cell development, activation and di↵erenti-
ation; signal transduction
Hematopoietic cells (not platelets and erythrocytes) [9]
CD11b Integrin alpha M, CR3A, ITGAM Cell adhesion; apoptosis; chemotaxis Granulocytes, monocytes, natural killer cells, T- and B-cells,
dendritic cells
[9]
Other markers
NG2 Neuron-glial antigen 2 Pericyte marker expressed on the surface of MSCs Neural progenitors, MSCs [27]
CD146 MCAM, S-Endo1, A32 antigen, MUC18 Pericyte marker , intracellular adhesion, promotes tumor
progression in many cancers
Endothelial cells, follicular dendritic cells, activated T-cells,
smooth muscle, MSCs
[27, 26]
CD106 VCAM1, L1CAM Adhesion of leukocytes; transmigration and costimulation of
T-cells
Activated endothelial cells and follicular dendritic cells [30]
STRO-1 - Cell membrane proteine, which translocates due to intracel-
lular calcium depletion
MSCs, endothelial cells [31, 32]
CD271 Nerve growth factor receptor, p75NTR Regulation of neuronal development (growth, migration, dif-
ferentiation, apoptosis)
Schwann cells, neurons, bone marrow-derived MSCs [33]
EGFR Epidermal growth factor receptor Tyrosine kinase receptor Epithelial cells [34]
PDGFR↵ Platelet-derived growth factor receptor, alpha polypeptide Tyrosine kinase receptor [35]
CD38 ADP ribosyl cyclase 1 Regulation of cell activation; proliferation and adhesion Variable expression on most hematopoietic and some non-
hematopoietic cells. High expression: plasma cells, early T-
and B-cells, natural killer cells, microglial cells
[36]
CD44 Epican, HUTCH-I, LHR, PGP-1, ECMR-III Regulation of leukocytes (rolling, homing, aggregation, ad-
hesion to endothelial cells, stromal cells, and extracellular
matrix)
Most lympho-hematopoietic cells [30]
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hand evades the limitation of spectral overlap using stable heavy metal isotopes instead of flu-
orophores. This technique combines classical flow cytometry with mass spectrometry. CyTOF
enables profiling of currently up to 40 surface markers at the same time on a per cell basis. Even
more, mass cytometry has theoretically over 120 detection channels available which in future
can be used as more isotopes become accessible. Mass cytometry enables profiling of function
and phenotype in both, cells of healthy and diseased condition. So far, this technique has found
application in research of immunology, oncology, haematology and drug development [29].
Figure 1: Cytometry by time-of flight workflow. A Cells stained with elemental isotope-labelled
probes (ICPs) enter the nebulizer B, where the sample becomes aerosolized. The resulting aerosol
droplets are introduced into the C ICP torch where they become vaporized, atomized and ionized.
The radiofrequency (RF) quadrupole ion guide D removes low-mass ions. In the time-of-flight
chamber (TOF, E ), ions are separated according to their mass to charge ratio resulting in a mass
spectrum F identifying and quantifying each isotope on single cell basis G. H The data can now
be further analysed [29].
The first step in the mass cytometry workflow is the staining of the cells with elemental-
isotope-labelled antibodies (Fig. 1). This liquid sample is directed into the nebulizer, where it
becomes desolvated into single-cell aerosol droplets. These are then introduced into the isotope-
conjugated probes (ICP) torch for vaporization, atomization and ionization. Next, the radiofre-
quency (RF) quadrupole ion guide removes low-mass ions in order to achieve an ion cloud enriched
for the probe isotopes. Entering the time-of-flight (TOF) chamber, the ion cloud is accelerated
towards a time-resolved detector separating the ions according to their mass to charge ratio.
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Hence, the generated mass spectrum represents the quantity and identity of each isotope on a
single cell basis. In the end, the produced .fcs files are available for data analysis, for example
on a cloud-based platform named Cytobank [29].
For the analysis of the high dimensional data produced by a CyTOF machine, pre-processing
is required, which includes data transformation, normalization, debarcoding, and gating. After
these first steps, the data is visualized making use of clustering based methods or dimensional-
ity reduction algorithms. The latter involves Principal Component Analysis (PCA) as well as
T-Stochastic Neighbour Embedding (t-SNE) algorithms. PCA is based on the presumption that
the relationship between the analysed parameters is linear. Thus, it calculates a smaller amount
of parameters preserving the variability of the original data [37]. t-SNE in contrast consists of a
non-linear approach visualizing similarities of cells on the basis of their marker expression in a
two- or three-dimensional scatter plot. Related cells are situated closer to each other than unre-
lated cells enabling identification and characterization of smaller subpopulations [29]. Further to
dimensionality reduction techniques, clustering based method can be applied for a visualization
of mass cytometry data. Spanning-tree Progression of Density-Normalized Events (SPADE), for
example, visualizes characteristics of cell subsets in a coloured hierarchical tree. However, this
algorithm is not able to preserve single-cell resolution [37]. A second approach for clustering
provides FlowSOM, an algorithm based on a self-organizing map providing several visualiza-
tion options like tree structures or star charts [38]. A third algorithm called Citrus generates
a dataset including all data from di↵erent samples, out of which cell populations can be deter-
mined by hierarchical clustering of phenotypically similar cells [37]. This means rephrased that
Citrus identifies stratifying subpopulations. Another approach to analyse mass cytometry data
is cell development modelling. Wanderlust and Phenograph are algorithms to analyze cellular
di↵erentiation processes [37].
A recently developed approach presents CellCnn, which allows detecting rare cell populations
by representation learning [39]. CellCnn is able to determine rare cell subsets associated with
a prior known phenotype (for instance healthy or diseased condition) from high dimensional
measurements on a single cell basis. In order to achieve an association between the input of
single cell measurements and the known phenotype the algorithm makes use of a convolutional
neural network (Fig. 2). This network learns to represent a subpopulation through molecular
profiles (filters) of single cells in terms of their frequency or presence. The single cells are
associated with a phenotype [39] (Fig. 2). With this novel algorithm, for example, rare natural-
killer-cell-subpopulations a liated with cytomegalovirus infection have been identified [39].
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A B
C D E
Figure 2: Illustration of CellCnn [39]. A Architecture of the convolutional neural network.
CellCnn takes inputs of individual-cell measurements, which are assigned to a group connected
with a phenotype. In the convolutional layer, node activities are defined as weighted sums over
molecular profiles of individual cells. In the pooling layer the frequency (= mean pooling) or
the presence (= max pooling) of particular cell subsets are estimated. The output layer of the
neural network evaluates the phenotype. Network training improves weights to correspond to
molecular profiles of significant cell subpopulations allowing annotating individual cells to a cell
subset (cell-filter response). B Cell-filter response for single cells. For example, marker profile of
cell one matches with filter 1 and therefore results in a high (red) cell-filter response (low filter
response = grey). C t-SNE projection coloured based on the cell filter response of individual
cells allowing to distinguish density based clusters D. E Greatest di↵erential abundance between
the whole cell-population and the chosen cell subpopulations using the Kolmogorov-Smirnov
two-sample test [39].
1.4 Aims of Doctoral Thesis
Using MSCs in regenerative medicine for therapeutic applications in orthopaedics is a highly
promising approach. In particular, adipose tissue has been determined as an excellent source of
multipotent mesenchymal stem cells. These cells can be potentially used for improving fracture
healing in critical size bone defects. However, ASCs consist of a heterogeneous cell population
covering dissimilar stem and progenitor cells of variable di↵erentiation potentials. For this reason,
it is of paramount importance to identify cell subsets more prone to osteogenic di↵erentiation
potentials to realize better bone regeneration in defects, especially in critical size bone defects.
The aim of this Doctoral Thesis is to scrutinize the heterogeneous composition of human ASCs
to determine specific subpopulation(s) with an enhanced capability to osteogenic di↵erentiation.
Such specific subpopulation(s) could be used to ameliorate healing in critical size bone defects
as standard procedures are not su cient for a positive outcome. For this purpose, the following
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approaches were pursued:
• Analysis of osteogenic di↵erentiation of 20 human ASC lines using the innovative technique
of mass cytometry operating with an already established antibody panel including MSC
and osteogenic markers and already optimized established protocols.
• Perform developmental paths in order to monitor expression of di↵erent protein markers
during osteogenic di↵erentiation in the 20 human ASC lines.
• Determination of a combination of markers characteristic for the subpopulation of ASCs
with enhanced osteogenic potential.
• In vitro adipogenic di↵erentiation of several ASC lines and analysis with real-time quanti-
tative PCR of MSC and adipogenic markers.
• In vitro chondrogenic di↵erentiation of several ASC lines.
1.5 Previous work
This Doctoral Thesis uses the data obtained in the author’s Master Thesis [40]. That work
performed an osteogenic di↵erentiation experiment with adipose-derived stem cells using the
CyTOF technique. This Doctoral Thesis performs a more thorough analysis of the data set
using new state-of-the-art algorithms. This gives further evidence to the assumption that specific
subpopulations more prone to osteogenic di↵erentiation within the heterogeneous population of
ASCs exist suggested in the author’s Master Thesis are valid.
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2 Methods
The following methods are identical to the ones used in the Author’s Master Thesis [40] and
were complemented and adapted for this Doctoral Thesis which is a continuation of that work.
2.1 Generation and culture of human adipose-derived stem cells
Thirty adipose tissue samples were obtained from healthy, not diabetic human donors undergoing
lipoaspirations and lipectomies [41, 25]. Twenty-six patients were female and four were male.
From those fat tissues adipose-derived stem cell lines (ASCs) were established in the laboratory.
21 cell lines were used for this Doctoral thesis. Part of them have been previously characterized
[41, 25] whereas others were characterized for this project. Human ASCs were cultured in Dul-
becco’s Modified Eagle Medium (DMEM, supplemented with 10% of Fetal Calf Serum (FCS), 1%
of antibiotics: 100x Penicillin, 100x Streptomycin, and 1% L-glutamine 200nM: ASC Medium),
which was changed every 2-3 days. Cells were passaged when they reached about 80% confluence
with 1x Trypsin for 5min at 37 C. Cells were incubated in an atmosphere with 95% humidity and
5% CO2 at 37 C. ASCs were frozen in ASC Medium supplemented with 1% dimethyl sulfoxide
(DMSO). All experiments were performed with ASCs below passage 10.
2.2 Reverse transcription and real-time quantitative PCR
RNA was isolated using RNeasy mini Kit (Qiagen) following the manufacturer’s instructions.
After isolation, reverse transcription was carried out with a GeneAMP PCR System (2hours
50 C, 10min 72 C) using 0.5g RNA, 0.5 g/ul oligo-dT primers, dNTP mix (10 mM), DTT (0.1M),
5xFS Bu↵er, RNA inhibitor (20 U/ul) and SuperScript III (200 U/ul). Real-time quantitative
PCR (RTQ-PCR) was performed using SYBR Green and specific primers (Tab. 2) with a Rotor
Gene PCR machine. Cycling conditions were: 95 C for 5s, 60 C for 30s, and 72 C for 30s, for a
total of 40 cycles. Analysis of the melting curves excluded unspecific amplification and primer
dimer formation. Gene expression was normalized to GAPDH expression and calculated using
the 2   ct and 2  ct/10 3 methods [42].
2.3 Osteogenic di↵erentiation
In order to assess osteogenic di↵erentiation, 21 ASC lines were cultured with StemPro R  Osteo-
genesis Di↵erentiation Kit (Gibco) for a period of 21 days. The medium was changed every 3-4
days. Cells were cultured in 6-well plates and collected for gene expression analysis at the fol-
lowing time points: day 0 (d0), d1, d2, d3, d4 (200000 cells/well), and d7, d14, d17, d21 (100000
cells/well). In order to collect an equal amount of cells at these time points, late time points were
seeded with less cells as they were cultured longer. RNA was extracted as described before and
gene expression was monitored by RTQ-PCR (Sec. 2.2). For the detection of calcium deposition,
cells were cultured in 24-well plates (10000 cells/well). Cells to be stained with Alizarin red and
16
Table 2: Human primer list.
Gene Forward primer Reverse primer
GAPDH 5’-ACCACAGTCCATGCCATCAC-3’ 5’-TCCACCACCCTGTTGCTGTA-3’
CD105 5’-CAGCAGTGTCTTCCTGCATC-3’ 5’-AGTTCCACCTTCACCGTCAC-3’
CD73 5’-CTCCTCTCAATCATGCCGCT-3’ 5’-CCCAGGTAATTGTGCCATTGT-3’
CD44 5’-GATCCACCCCAATTCCATCTGTGC-3’ 5’-AACCGCGAGAATCAAAGCCAAGGCC-3’
CD106 5’-GGACCACATCTACGCTGACA-3’ 5’-TTGCATGTGATCGGCTTCCC-3’
CD146 5’-CAACAGCACCTCCACAGAGA-3’ 5’-GTGATCTCCTGCTTCCCTGA-3’
CD90 5’-TGAATACAGACTGCACCTCCC5-3’ 5’-CTTGACGGGTGAGGCTAGGA5-3
EGFR 5’-GGTGAGCCAAGGGAGTTTGT-3’ 5’-TCTTAGGCCCATTCGTTGGAC-3’
PDGFR↵ 5’-CGGAGGAGAAGTTTCCCAGAG-3’ 5’-CTGCTCACTTCCAAGACCGT-3’
Osteocalcin 5’-CACTCCTCGCCCTATTGGC-3’ 5’-CCCTCCTGCTTGGACACAAAG-3’
AP 5’-CTGGTAGTTGTTGTGAGCAT-3’ 5’-CCCAAAGGCTTCTTCTTG-3’
RUNX2 5’-GAACCCAGAAGGCACAGACA-3’ 5’-GGCTCAGGTAGGAGGGCT-3’
PPARy 5’-CCT GCT ACA AGC CCT GGA-3’ 5’-CTG CAC GTG TTC CGT GAC-3’
FAB4 5’-GTG GGC TTT GCC ACC A-3’ 5’CCT GGC CCA GTA TGA A-3’
APM1 5’TGT TGC TGG GAG CTG TTC TAC TG-3’ 5’-ATG TCT CCC TTA GGA CCA ATA AG-3’
control cells (cultured with ASC medium) were both cultured in triplicates for the time points
14, 17, and 21 days.
2.3.1 Detection of calcium deposition by Alizarin Red staining
As mentioned before, calcium deposition was assessed after 14, 17, and 21 days of di↵erentiation.
First of all, cells were washed with PBS, fixed with 4% formalin (Roth) for 30min at room
temperature (RT) and then incubated with Alizarin Red solution (pH 4.16, 40mM; Sigma) for
20min at RT. Afterwards cells were washed with distilled water (ddH2O) and let dry. Pictures
were taken with an Epson expression 1640 XL scanner.
2.4 Adipogenic di↵erentiation
Adipogenic di↵erentiation was induced with StemPro R  Adipogenesis Di↵erentiation Kit (Gibco).
As for the osteogenic di↵erentiation 21 human ASCs were cultured either into 6-well plates (for
RNA analysis) or in triplicates into 24-well plates for detection of lipids by Oil Red O staining.
The medium was changed every 3-4 days. The same amount of cells was distributed as described
for osteogenic di↵erentiation. RNA samples were taken at d0, d1, d2, d3, d4, d7, d14, d17, d21
whereas at day 14, 17, and 21 lipids were stained with Oil Red O.
2.4.1 Detection of lipids by Oil Red O staining
For the detection of lipids cells were washed with PBS and then fixed with 10% formalin (Roth)
for 5min. The formalin was removed and added fresh to the cells for another 60min at RT. After
fixation, cells were washed twice with ddH2O and then rinsed twice with 60% isopropanol. Cells
were thereafter let dry completely and then incubated for 10min with Oil Red O working solution
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(6ml Oil Red O stock solution plus 4ml ddH2O). Next cells were washed four times with ddH2O.
For quantification of adipogenic di↵erentiation pictures were taken (in 500ul ddH2O) using Leica
microscope DMIL LED with Leica camera DFC 425 C. For each well 12 pictures were taken
at a magnitude of 20X, Oil Red stained cells were counted and the mean of the triplicates was
reported.
2.5 Chondrogenic di↵erentiation
Chondrogenic di↵erentiation was induced by StemPro R  Chondrogenesis Di↵erentiation Kit (Gibco).
In contrast to the osteogenic and the adipogenic di↵erentiation, the 21 cell lines were given into
TPP Tubespin Bioreaktors with filters (200000 cells/tube) in order to assess cartilage formation.
Cells were centrifuged at 500x g for 10min at RT and cultured as pellets in chondrogenic induc-
ing medium. For each time point (day 14, d17, and d21) two tubes were prepared: one with
chondrogenic medium and the other one with ASC medium serving as a control. The medium
was changed every 3-4 days.
2.5.1 Detection of cartilage by Alcian Blue staining
After 14, 17, and 21 days, cells cultured in chondrogenic conditions formed pellet-like clumps at
the bottom of the tube. Carefully the pellets were washed with PBS and fixed with 10% formalin
(Roth) for 20min at RT. Afterwards the pellets were transferred into 1.5ml tubes, embedded
into 2% agarose and incubated on ice for 30min. Afterwards the solid agaroses containing the
cell-clumps were transferred into histocassettes, put in 70% ethanol and stored at -20 C. Then
histocasettes were washed in PBS and given into a tissue processing apparatus. Thereafter, the
agaroses with the cells were embedded into liquid para n, left at RT until they were solid and
then stored at -20 C. Para n wax sections were cut at 5 um and given onto microscope slides.
The slides were depara nized via incubation in xylol for two times, in 100% ethanol three times,
in 96% ethanol one time and once in 70% ethanol. After depara nization, cells were rehydrated
in PBS. Then, slides were incubated in 1% Alcian Blue solution for 60min at RT. Next slides
were rinsed three times with 0.1% HCl, neutralized with ddH2O, and air dried. Pictures were
taken using Leica DM6000B microscope and Leica DFC 425 C camera.
2.6 Analysis of human adipose-derived stem cells with cytometry by
time-of-flight
2.6.1 Antibody panel
For the analysis of undi↵erentiated and osteogenic di↵erentiated human ASC lines by CyTOF
an antibody panel was used which was already established in the laboratory prior this Doctoral
Thesis (Tab. 3, [43, 40]).
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Table 3: Antibody panel.
Antigen tar-
get (human)
Location of
the antigen
Clone num-
ber
Company Elemental
isotope
Final con-
centration
(for 1mio
cells in
100µ`)
Final con-
centration
(for >10mio
cells in
300µ`)
CD19 Surface HIB19 Biolegend 142Nd 1/1600 1/800
CD11b Surface ICRF44 Fluidigm 144Nd 1/1600 1/800
CD73 Surface AD2 Biolegend 146Nd 1/800 1/400
CD146 Surface P1H12 Fluidigm 155Gd 1/100 1/50
NG2 Surface 7.1 Santa Cruz 150Sm 1/400 1/200
CD45 Surface HI30 Fluidigm 154Sm 1/3200 1/1600
CD79↵ Surface HM47 Biolegend 156Dy 1/800 1/400
CD106 Surface STA Biolegend 158Gd 1/800 1/400
PDGFR↵ Surface D13C6 Fluidigm 160Gd 1/800 1/400
CD90 Surface 5E10 Fluidigm 161Dy 1/800 1/400
STRO-1 Surface STRO-1 Biolegend 163Dy 1/800 1/400
CD271 Surface ME20.4 Biolegend 165Ho 1/800 1/400
EGFR Surface AY13 Biolegend 167Er 1/800 1/400
CD44 Surface IM7 Fluidigm 171Yb 1/800 1/400
CD38 Surface HIT2 Fluidigm 172Yb 1/200 1/100
CD14 Surface M5E2 Fluidigm 175Lu 1/800 1/400
CD105 Surface 43A3 Biolegend 176Lu 1/800 1/400
RUNX2 Nuclear S533 GeneTex
(GTX81326)
153Eu 1/800 1/400
AP Cytoplasmic TRA-2-49/6E Stem Cells
(60066)
169Tm 1/1600 1/800
2.6.2 Osteogenic di↵erentiation experiment with 20 human ASC lines
For the osteogenic di↵erentiation experiment 20 human ASC lines were cultured over a period
of 4 days under osteogenic di↵erentiation conditions. For the time points day 0, d1, d2, d3, d4
one 10cm dish containing 1.5 mio cells was prepared for all the 20 ASC lines for a total of 100
dishes in culture. Cells were split into the dishes at d0 and cultured with StemPro R  Osteogenesis
Di↵erentiation medium, each plate with 8ml medium which was never changed over the period
of the experiment (4 days). Day 0 cells (that means untreated cells) were immediately collected
and further treated (Fig. 3).
Barcoding As depicted in Fig. 3, each day cells were collected and barcoding was performed
using Cell-ID 20-Plex Pd Barcoding Kit (Fluidigm). A barcoding plan was developed prior
starting the experiment (Tab. 4). For that, cell lines were divided into good, bad and intermediate
groups based on Alizarin red staining from 21 days of osteogenic di↵erentiation as described
before. Since the barcoding kit had 20 di↵erent codes we ended up having 5 tubes each containing
4 cell lines with 5 time points. Within one tube, each cell line had its own barcode for each time
point (Tab. 4).
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Figure 3: Illustration of the osteogenic di↵erentiation of 20 human ASC lines followed by CyTOF
analysis. After cell staining at day 4 cells were stored at 4 C until CyTOF analysis was performed.
Table 4: Barcoding plan.
barcode
cell line name di↵erentiation potential day 0 day 1 day 2 day 3 day 4
Tube 1 contains cell lines:
F4 good 1 5 9 13 17
F19 bad 2 6 10 14 18
F8 intermediate 3 7 11 15 19
F9 not determined yet 4 8 12 16 20
Tube 2 contains cell lines:
F5 good 1 5 9 13 17
F27 bad 2 6 10 14 18
F14 intermediate 3 7 11 15 19
F16 not determined yet 4 8 12 16 20
Tube 3 contains cell lines:
F15 good 1 5 9 13 17
F10 bad 2 6 10 14 18
F17 intermediate 3 7 11 15 19
F23 not determined yet 4 8 12 16 20
Tube 4 contains cell lines:
F18 good 1 5 9 13 17
F29 intermediate 2 6 10 14 18
F32 intermediate 3 7 11 15 19
F30 not determined yet 4 8 12 16 20
Tube 5 contains cell lines:
F22 good 1 5 9 13 17
F28 intermediate 2 6 10 14 18
F31 intermediate 3 7 11 15 19
F11 intermediate 4 8 12 16 20
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The barcoding protocol was the following: cells were washed with PBS and incubated with
Cell-ID
TM
Cisplatin for 10min at RT. Afterwards cells were fixed with MaxPar R  Fix I Bu↵er
for 10min at RT, washed with MaxPar Barcode Perm Bu↵er, and incubated with its specific
barcode (Tab. 4) for 30min at RT.
Staining protocol At the last day of the experiment, all barcoded cell lines were pooled into
the 5 tubes according to the barcoding plan (Fig. 3 and Tab. 4) to be stained all together. Cell
staining was performed with the antibody panel (Tab. 3) following the 3 protocols fromMaxPar R :
Cell Surface Staining Protocol, Cytoplasmic/Secreted Antigen Staining Protocol, and Nuclear
Target Staining Protocol (Fluidigm) as established prior in the laboratory [40]. Nevertheless,
some adjustments at the protocol were performed since the amount of cells was much higher
than what usually stained: Fixation times for each staining protocol were reduced and staining
were performed in 300ul end volume instead of 100ul and antibody concentrations were doubled
(Tab. 3). In short, cells were incubated with the cell surface antibody cocktail for 30min at
RT. Afterwards, cells were washed with MaxPar R  Cell Staining Bu↵er. Next, cytoplasmic
antigen staining was performed: cells were fixed with MaxPar R  1X Fix I Bu↵er for 10min at RT
(instead of 30 min). Then, cells were washed in MaxPar R  Perm-S-Bu↵er and incubated with
the cytoplasmic antibody (Tab. 3) for 30min at RT. Upon washing with MaxPar R  CSB for the
nuclear target staining, cells were fixed with eBioscience FoxP3 Fixation/Permeabilization Bu↵er
(1X) for 10min at RT (instead of 45min). Cells were washed with eBioscience Permeabilization
Bu↵er and incubated with the nuclear target antibody (Tab. 3) for 60min at RT. After the
staining, cells were washed in MaxPar R  CSB and resuspended in MaxPar R  Fix and Perm Bu↵er
containing Cell-IDTM Intercalator-IR and stored at 4 C until data acquisition. Data acquisition
was made with a CyTOF 2 Mass Cytometer by expert people at the Mass Cytometry Facility
of the University of Zurich.
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3 Materials
The materials used for the experiments are listed in Table 5.
Table 5: Material list.
Materials Company Catalog number
Cell culture
10cm dishes Corning
6-well plates Costar 3516
24-well plates Thermo scientific 1 42475
15 ml tubes TPP 91014
Dulbeccos modified eagle medium-DMEM Pan Biotech P04-03550
100x Penicillin Biowest L0022-100
100 x Streptomycin Sigma
L-glutamine 200nM Sigma G7513
Fetal calf serum (FCS) Pan
Trypsin 10x Sigma T4174
Dimethylsulfoxide-DMSO Sigma D4540
PBS Kantonsapotheke Zu¨rich
Di↵erentiation medium
StemProR  Osteogenesis Di↵erentiation Kit Gibco A-10072-01
StemProR  Adipogenesis Di↵erentiation Kit Gibco A-10070-01
StemProR  Chondrogenesis Di↵erentiation Kit Gibco A-10071-01
Staining
Oil Red O Sigma O 0625
Alizarin red Sigma A5523
Formalin Roth
Alcian Blue Sigma Aldrich A5268
RNA Isolation, reverse transcritpion, qPCR
RNase mini kit Qiagen 74106
Qiashredder(250) Qiagen 79656
Oligo-dT Primers Invitrogen
dNTP mix Qiagen 201900
DTT Qiagen
5 x FSB Invitrogen
RNA Inhibitors AB 100021540
SuperScriptR  III Invitrogen 18080093
Sybr Green Qiagen 205076
CyTOF
1.6% formalin Roth
Cell-ID 20-Plex Pd Barcoding Kit Fluidigm 201060
MaxParR  Cell Staining Bu↵er Fluidigm 201068
MaxParR  Fix and Perm Bu↵er Fluidigm 201067
MaxParR  Water Fluidigm 201069
Cell-ID
TM
Intercalator-Ir Fluidigm 201192A [125M] or 201192B [500 M]
Cell-ID
TM
Cisplatin Fluidigm 201064
MaxParR  Fix I Bu↵er (5X) Fluidigm 201065
MaxParR  Perm-S Bu↵er Fluidigm 201066
eBioscience FoxP3 Fixation/Permeabilization Con-
centrate and Diluent
eBioscience 00-5521
eBioscience Permeabilization Bu↵er (10X) eBioscience 00-8333
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4 Results
In general, the capability of bone fracture healing di↵ers substantially among di↵erent patients.
On the one hand some patients are able to regenerate bone rapidly, on the other hand other
patients experience delayed or even non-union. Why are there such di↵erences? In orthopaedic
surgery, adipose-derived mesenchymal stem cells (ASCs) are reported to be a highly e↵ective
basis for bone regeneration. Investigation of ASCs obtained from several patients show that
all of them fulfil the criteria in accordance with the International Society for Cellular Therapy
(ISCT) of mesenchymal stem cells [9], but they range strongly in their osteogenic di↵erentiation
potential. This leads to the question, why ASCs isolated from di↵erent patients with a defined
marker expression (from the ISCT) show varying abilities for bone regeneration.
4.1 Characterization of adipose-derived stem cells
In order to have a better understanding why such di↵erences in bone regeneration exist, a
characterization of ASCs isolated from 21 patients was performed. First, gene expression levels
of selected markers were measured in undi↵erentiated ASCs using real-time quantitative PCR
(Fig. 4). Classical MSC markers such as CD73, CD105, CD90, and CD44 were measured. As
depicted in Fig. 4, the expression profiles of the mentioned markers show varying levels in the
di↵erent ASC lines and therefore confirmed their heterogeneity. The marker CD90 generally
showed a low expression profile in all the cell lines whereas CD105 showed a range of low to high
expression. For example, the line F09 displayed a low expression in the markers CD73, CD105,
and CD90 but had a high expression in CD44. In contrast, F32 had low expression levels for
CD73 and CD90, and intermediate expression levels in CD105 and CD44.
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Figure 4: Heatmap for mesenchymal stem cell markers from 21 ASC lines in their undi↵erentiated
state. Expression profiles were evaluated using the 2  ct/10 3 method [42].
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For further characterization, the multipotency of the 21 ASC lines was investigated. To be
precise, each cell line was cultured in particular conditions in order to assess their ability to
di↵erentiate into osteoblasts, adipocytes, and chondrocytes.
4.1.1 Osteogenic di↵erentiation
In order to assess the di↵erentiation capacity into osteoblasts, 19 ASC lines were cultured in
osteogenic conditions for 14, 17, and 21 days. Calcium deposition was evaluated by Alizarin red
staining at the indicated time points (Fig. 5). Five cell lines already showed a calcium deposition
at day 14 and 17 (Fig. 5A). Therefore, they were classified as cell lines with a good osteogenic
di↵erentiation ability. Six lines were categorized as bad osteogenic di↵erentiation lines, since
Alizarin red staining was negative even after 21 days of di↵erentiation (Fig. 5C). The remaining
8 cell lines were positive for Alizarin red staining only after 21 days of di↵erentiation and were
therefore categorized as intermediate di↵erentiating lines (Fig. 5B). The classification in good,
bad, and intermediate osteogenic di↵erentiating lines is summarized in Tab. 6.
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d14
d17
d21
F04 F05 F15 F18 F22
F19 F27F10F09
F30
F25
F08 F14 F17 F28
F29 F32F31
F11
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d17
d21
d14
d17
d21
control 
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B
C
Figure 5: In vitro osteogenic di↵erentiation over a period of 21 days for 19 ASC lines. Cells were cultured in triplicates for both: control
cells in ASC medium (left) and cells di↵erentiating in osteogenic medium (right). Alizarin red staining was performed after 14, 17, and
21 days. ASCs were classified in good (A), intermediate (B), and bad (C ) di↵erentiating lines.
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Table 6: 19 ASC lines classified into three groups (good, intermediate, and bad) according to their
calcium deposition detected by Alizarin red staining after 21 days of osteogenic di↵erentiation.
good intermediate bad
F04 F28 F19
F05 F29 F27
F15 F32 F10
F18 F14 F09
F22 F08 F30
F17 F25
F31
F11
Next, gene expression of selected markers was assessed for 21 ASC lines at di↵erent time
points during osteogenic di↵erentiation over 21 days (Fig. 6). The stated mesenchymal stem
cell markers from the ISCT CD73, CD105 and CD90 as well as MSC marker CD44 were in
general down-regulated over the period of 21 days of di↵erentiation. Nevertheless, the expression
levels of these markers di↵ered greatly between the ASC lines. For example, the ASC line F04
showed a down-regulation of the markers CD73 and CD105 already at d7, whereas CD90 level
was not decreased until d17. CD44 revealed a fluctuating profile in this line. In contrast, the line
F27 presented increasing expression levels for all four mesenchymal stem cell markers. As for
the ISCT markers, also osteogenic di↵erentiation markers displayed dissimilarities in expression
levels (Fig. 6). For example, the line F08 showed increasing expression of osteocalcin and
RUNX2 from the first and for AP from the second day of di↵erentiation. In opposition to F08,
F11 displayed an upregulation of AP only at d14, whereas the markers osteocalcin and RUNX2
were not up-regulated over the whole time of di↵erentiation. For F17 no trend could be observed,
all three osteogenic di↵erentiation markers showed a fluctuating profile.
4.1.2 Adipogenic di↵erentiation
As for the osteogenic di↵erentiation, also adipogenic di↵erentiation was performed for the same
21 ASC lines over a period of 21 days. Fat deposition was assessed at day 14, d17, and d21
by Oil red staining and gene level expression was measured at the same time points like in the
osteogenic di↵erentiation (see Sec. 4.1.1).
As in the osteogenic di↵erentiation, also in the adipogenic di↵erentiation heterogeneity could
be observed (Fig. 7). For example, F30 showed a slow increase in lipid formation over the 21
days of di↵erentiation, whereas F05 already displayed many lipid aggregations at day 14 (Fig.
7A). Di↵erences could also be seen in the quantification of the adipogenic di↵erentiation (Fig.
7B). F11 and F23 for example showed poor lipid formation, whereas F14 and F16 presented a
considerably higher adipogenic di↵erentiation.
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Figure 6: Heatmaps for 21 ASC lines for stem cell marker expression (CD73, CD105, CD90,
and CD44) and osteogenic di↵erentiation marker expression (Osteocalcin, RUNX2, and AP).
Expression levels (low= green, high = red) were measured at day 0, d1, d2, d3, d4, d7, d14, d17,
and d21. Depicted is the fold change compared to day 0. Not yet determined marker expression
is indicated with a white color.
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Figure 7: A Examples of Oil red O stainings from in vitro adipogenic di↵erentiation for the lines
F32, F30, F05, and F18 at day 14, d17, and d21. Pictures were taken with a magnification of
20X with Leica microscope DMIL LED with Leica camera DFC 425 C. B Quantification of lipid
aggregates at 17 and 21 days of adipogenic di↵erentiation from 21 ASC lines. Depicted are the
averages of the triplicates, error bars indicate standard deviation of the mean.
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Also gene expression levels of di↵erent markers during adipogenic di↵erentiation showed dif-
ferences between the 21 ASC lines (Fig. 8). Expression levels of the stem cell markers CD73,
CD105, CD90, and CD44 depicted a general trend of downregulation over the 21 days. For ex-
ample, F08 showed a downregulation for CD73, CD90, and CD44, but CD105 increased over the
period of di↵erentiation. In contrast, in F15 the markers CD73 and CD44 were downregulated,
but CD105 increased slightly, and CD90 showed a general high expression level over the 21 days
of di↵erentiation. Di↵erences in expression were also observed in the adipogenic di↵erentiation
markers. All of them showed a trend of upregulation, although the beginning and the intensity of
the upregulation varied (Fig. 8). Expression level of PPARy in F31 for example was increasing
already at day 2, expression level for FAB4 and APM1 at day 3. The ASC line F23 on the other
hand showed only a slight upregulation of all three markers. F08 displayed a high expression of
APM1 towards the end of the di↵erentiation period. PPARy showed only a strong upregulation
at day 21 and FAB4 was only slightly increased in this line. Overall, the potential for adipogenic
di↵erentiation varied considerably between the 21 investigated cell lines.
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Figure 8: Heatmaps for 21 ASC lines for stem cell marker expression (CD73, CD105, CD90, and
CD44) and adipogenic di↵erentiation marker expression (PPARy, FAB4, and APM1). Expression
levels (low= green, high = red) were measured at day 0, d1, d2, d3, d4, d7, d14, d17, and d21.
Depicted is the fold change compared to day 0. Not yet determined markers are indicated with
a white colour.
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4.1.3 Chondrogenic di↵erentiation
As a last step, also chondrogenic di↵erentiation was performed with 21 ASC lines. Cartilage
formation was detected by Alcian blue staining after 14, 17, and 21 days. As depicted in Fig.
9 for three cell lines, only small di↵erences could be seen. For example: Alcian blue staining
for F25 was generally stronger than in F23, but considerable di↵erences could not be detected.
Therefore, an optimization of the culturing and staining protocols are needed in order to better
catch di↵erences between the ASC lines.
F27
d14 d17 d21
F23
F25
Figure 9: Cartilage formation detection by Alcian blue staining for three ASC lines (F27, F23,
F25) during chondrogenic di↵erentiation at day 14, d17, and d21. Pictures were taken with a
Leica DM6000B microscope and Leica DFC 425 C camera at a magnitude of 5X.
To sum up, we showed that significant di↵erences exist between the investigated 21 ASC
lines not only in their in vitro trilineage potential, but also in their marker expression patterns.
According to these observations, it can be assumed that the composition of the di↵erent ASC
lines is highly heterogeneous and that they are probably composed of smaller subpopulations
with dissimilar di↵erentiation abilities. As our primary interest was to detect why di↵erent
patients have di↵erent outcomes in bone regeneration, we came to the conclusion that Alizarin
red staining and real-time quantitative PCR allow only evaluation of the whole population of the
ASCs without taking the existence of subpopulations into account. It is to assume that distinct
small subpopulations might have enhanced potential for osteogenic di↵erentiation. These cells
would be the ones of interest to be further investigated. For this purpose, the innovative technique
of cytometry by time-of-flight (CyTOF), which allows evaluation on a single cell basis, was used
to further analyse the selected 20 ASC lines.
4.2 Analysis of adipose-derived mesenchymal stem cells by CyTOF
CyTOF combines classical flow cytometry with mass spectrometry. This novel technology enables
therefore real-time analysis of individual cells, which were previously labelled with stable heavy
metal isotopes. In theory, mass cytometry has the advantage of having theoretically over 120
detection channels available.
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4.2.1 Analysis of undi↵erentiated adipose-derived mesenchymal stem cells
For the main CyTOF experiment, 20 human ASC lines were exposed to osteogenic medium over
a period of four days, collected, and stained with the established antibody panel which included
19 markers (Tab. 3). Data acquisition with mass cytometry provided high dimensional data.
The goal of the analysis of this data was to investigate whether the di↵erences between good
and bad di↵erentiating ASC lines, based on the outcomes of the Alizarin red staining, were also
present on the level of single cells.
The first aim of the CyTOF experiment analysis was to determine whether di↵erences be-
tween the two groups of ASC lines, namely the good and the bad, are already present in the
undi↵erentiated state of the cells. In order to analyse the multiparametric CyTOF data, dimen-
sionality reduction algorithm t-SNE was performed for the 20 ASC lines at day 0 (Fig. 10).
Figure 10 displays the marker distribution across the t-SNE map for all markers of the antibody
panel. Cells strongly expressing the stem cell markers CD73, CD90 and CD105 were located in
the upper left side of the cloud. Interestingly, the tyrosine kinase receptors PDGFRa, EGFR, as
well as NG2 displayed a similar pattern. Similarly, RUNX2 expressing cells were also located in
the upper left corner. The MSC negative markers CD45, CD14, and CD11b depicted no marker
expression. Surprisingly, CD19a MSC negative marker displayed a small percentage of cells with
high expression (Fig. 10).
In order to approach the question whether there are subpopulations more prone to di↵er-
entiate into osteoblasts, an algorithm which allows detecting rare cell subsets was needed. A
recent approach called CellCnn, which is based on representation learning, o↵ered a substantial
methodology to address this question [39]. CellCnn detects rare cell subsets associated with a
prior known phenotype (for example healthy or diseased condition) by means of a representation
learning approach using high dimensional measurements on a single cell basis as an input. In
order to achieve an association between the input of single cell measurements and the known
phenotype the algorithm makes use of a convolutional neural network. This network learns to
represent a subpopulation through molecular profiles (filters) of single cells in terms of their
frequency or presence. The single cells are associated with the phenotype [39].
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Figure 10: Distribution of the 19 markers across the t-SNE map for 20 ASC lines. Each point
represents one cell and they are colour-coded based on their abundance of the indicated marker
(red is highly expressed and blue stands for no expression).
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In our experimental setting, the classification in ”good” and ”bad” di↵erentiating ASC lines
according to the results of Alizarin red staining (Fig. 5) was used as the phenotype. For the
analysis, data from the good and the bad cell lines at day 0 were extracted. Then, CellCnn
was trained to be able to identify cell subpopulations that di↵er in the abundance between the
good and the bad group. Five cross-validation repetitions were carried out and three out of
them gave a consistent result: Two cell subpopulations were detected that di↵ered significantly
between the two groups. Figure 11 depicts the subpopulation which is more abundant in the
badly di↵erentiating cell lines on the t-SNE map (subpopulation 1). As it is clear to observe, the
MSC markers CD73, CD90, and CD105 are highly expressed by the cells in the upper left corner
of the t-SNE cloud. PDGFRa and EGFR are also highly positive in subpopulation 1 within the
same area of the cloud (Fig. 11). Interestingly, RUNX2 was also expressed in a similar way.
A small percentage of cells strongly expressed the markers CD44, STRO-1, CD146, and NG2,
whereas CD11b was less intense. The rest of the markers were not expressed in subpopulation 1
(Fig. 11).
CellCnn detected a second subpopulation, which was more abundant in good di↵erentiating
ASC lines (subpopulation 2, Fig. 12). In contrast to subpopulation 1, the MSC markers CD73,
CD90, and CD105 were expressed from a smaller amount of cells located in the middle left area
of the t-SNE cloud (Fig. 12). Another di↵erence is that a large percentage of cells in the lower
left corner of the t-SNE cloud was highly positive for alkaline phosphatase (AP). There were also
less cells expressing RUNX2 than in subpopulation 1.
Next, the marker abundance from the two selected subpopulations was compared to the
background as depicted in Fig. 13. The most obvious di↵erence between the two subpopulations
is the lack of AP expression in subpopulation 1, which was highly expressed in the subpopulation
2. Another example is CD73, which was expressed on a higher level in subpopulation 1 compared
to subpopulation 2 (Fig. 13).
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Figure 11: Distribution of the 19 markers across the t-SNE map for the selected subpopulation
1, which was found by CellCnn algorithm to be more abundant in badly di↵erentiating ASC
lines. Each point represents one cell and they are colour-coded based on their abundance of the
indicated marker (red is highly expressed and blue stands for no expression).
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Figure 12: Distribution of the 19 markers across the t-SNE map for the selected subpopulation
2, which was found by CellCnn algorithm to be more abundant in good di↵erentiating ASC
lines. Each point represents one cell and they are colour-coded based on their abundance of the
indicated marker (red is highly expressed and blue stands for no expression).
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subpopulation 1
subpopulation 2
A
B
Figure 13: Histograms of marker abundance of 19 markers. Depicted are the intensities of the selected populations (orange) by CellCnn
compared to the whole cell subpopulation (background, violet) calculated with the Kolmogorov-Smirnov (KS) two-sample test. A
Subopulation 1 is more abundant in bad di↵erentiating lines and B subpopulation 2 is more abundant in good di↵erentiating lines. The
heights are mode normalized.
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Another visualization of the two selected subpopulations is displayed in Fig. 14, where
the frequencies of the latter are shown within the bad and good ASC lines. The population
frequency of subpopulation 1 is noticeably higher in the bad lines compared to the good cell
lines. In contrast, subpopulation 2 is clearly more represented in the good ASC lines.
subpopulation 1 subpopulation 2
Figure 14: Frequencies (%) of the identified populations 1 and 2 in the bad (green) and the good
(orange) groups of di↵erentiating ASC lines at day 0.
In sum, CellCnn identified two subpopulations within the whole population of ASCs, which
di↵ered between good and bad ASC lines already in the undi↵erentiated state of the cells. Hence,
it is to assume that there exist probably two (or more not yet determined) subpopulations, whose
frequency and marker expression influence the ability for bone regeneration. Presence of subpop-
ulation 1 seems to inhibit osteogenic di↵erentiation by retaining the stem cell markers whereas
the cells in subpopulation 2 seem to be prone to di↵erentiate into osteoblasts showing a high
level of AP already at day 0. Thus, these observations clearly confirm the hypothesis, that the
ASCs obtained from di↵erent patients vary in the composition of subpopulations. Therefore,
it is to assume, that ASCs are truly highly heterogeneous concerning their composition of sub-
populations. In fact, it seems that the di↵erent bone healing formation abilities depend on the
frequencies of defined small subpopulations.
4.2.2 Analysis of di↵erentiating adipose-derived mesenchymal stem cell
As already reported in Sec. 4.2.1, ASCs showed even in their undi↵erentiated state dissimilarities
in the frequencies of di↵erent subpopulations between good and bad osteogenic di↵erentiating
ASC lines. In order to further investigate these di↵erences, the two by CellCnn identified sub-
populations which displayed di↵erent marker expression and frequencies between the two groups
of the cell lines were analysed over a period of four days of osteogenic di↵erentiation. In this
analysis setup, also the intermediate group was included. As displayed in Fig. 15A, the abun-
dances of the selected subpopulation 1 showed a di↵erent pattern in the population percentage
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in the course of the four days of di↵erentiation. In fact, the abundance in the bad lines generally
increased whereas the good lines displayed only a small upregulation. The intermediate lines
seemed to follow the trend of the good lines, as they had a similar abundance only on a slightly
higher percentage.
A B
Figure 15: Abundance of selected cell subpopulation 1 (A) and subpopulation 2 (B) in the bad
(blue), intermediate (green), and good (red) ASC lines during osteogenic di↵erentiation over four
days.
The selected subpopulation 2 also showed a di↵erent behavior over the four days of osteogenic
di↵erentiation between the di↵erent groups of cell lines (Fig. 15B). On the one hand, the good
and the intermediate cell lines showed a trend of upregulation in their abundances, on the other
hand, the bad lines had indeed an increased in the first two days, reaching almost the level of
the intermediate lines, but afterwards they decreased again.
Also of interest, it is to understand how behave the markers within the good, the intermediate,
and the bad, during the four days of di↵erentiation. AP for example showed a constant increase
over the four days in the good lines (Fig. 16A). In contrast, the bad lines show only a small
increase in their AP abundance (Fig. 16A). CD73 showed a general trend of downregulation over
the period of four days of osteogenic di↵erentiation, although to a larger extent in the good and
intermediate lines (Fig. 16B). In general, the abundance of CD73 is higher in the bad than in
the other two cell categories. In comparison to CD73, CD105 did not show obvious di↵erences in
their abundances between the di↵erent classified cell lines during osteogenic di↵erentiation (Fig.
16C).
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A B
C
Figure 16: Median expression value of AP (A), CD73 (B), and CD105 (C ) during osteogenic
di↵erentiation over a period of four days. Depicted are the abundances for the bad (blue), the
intermediate (green), and the good (red) classified ASC lines.
To sum up, the results of the mass cytometry analysis displayed that there are indeed dif-
ferences between good and bad osteogenic di↵erentiating cell lines. This is highlighted not only
in the four days of di↵erentiation, but also in the undi↵erentiated state of the ASCs. CellCnn
identified two subpopulations, which need to be deeper investigated in order to be able to clearly
explain why there are such big di↵erences between fracture healing outcomes of di↵erent patients.
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5 Discussion
5.1 Analysis of the heterogeneity of hASCs with multiparametric mass
cytometry data
Severe skeletal deficits are associated with a high rate of delayed or non-unions and represent
a tremendous clinical challenge [4, 5]. Particularly critical size bone defects, where bridging
of the fracture’s site remains incomplete without intervention, are still a demanding issue in
orthopaedics and reconstructive surgery [6]. Failure of bone regeneration can appear due to
substantial bone defects and pathological fractures, but can also be negatively influenced by
infection, systemic diseases, and inadequate blood supply [4]. Current therapeutic approaches to
achieve skeletal reconstruction involve autogenous, allogeneic, as well as prosthetic constituents.
At present, autogenous bone grafts, commonly collected from the crest of the ilium, combined
with alloplastic materials are regarded as the gold standard technique for non-healing bone in-
juries [4, 5]. However, this method brings around drawbacks such as donor site pain, morbidity,
and limited supply of bone graft [5]. A recent approach presented cell-based tissue engineering
with MSCs, which forged ahead its way in orthopaedic surgery. This technique has been inves-
tigated in both large and small animal models [6, 7]. In particular, adipose tissue is stated to be
an excellent source of MSCs. The advantages of ASCs are: The easy access for acquisition, the
satisfactory quantities of isolated cells, and the straightforward management in cell culture [20].
MSCs are stated to be heterogeneous not only regarding their protein expression, but also
due to their morphology and di↵erentiation abilities (reviewed in [24, 23]). These reviews re-
port for instance, that the defined MSC markers from the International Society for Cellular
Therapy (ISCT) were indeed present in every isolated cell, but interestingly at varying levels.
Clearly, these biomarkers define no inimitably feature for MSCs, but might rather mirror their
heterogeneity. Furthermore, di↵erentiation capabilities into specific cell types was reported to
be di↵erent in the isolated cells [44]. As clinical outcomes in fracture healing are known to di↵er
strongly among individuals, this observation could be an underlying reason. Besides, isolation
and culture protocols established for MSCs could also have an impact on the heterogeneous state
of the cells. Up to now, research groups used a large variety of protocols for MSCs. Therefore,
it is of contradictive nature to directly compare the characterization of MSCs coming from dif-
ferent studies. The protocols could have an influence, for instance, on marker expression among
slightly di↵erent culture conditions. Moreover, studies have shown that with the established
protocols, isolated MSCs not only consist of stem cells, but also of a variety of progenitor cells
[45, 44]. Thus, viewing the whole population of isolated cells as stem cells is unsuitable. Because
of the heterogeneous composition of MSCs, it is to assume, that MSCs may consist of smaller
subpopulations. If the occurrence of a subpopulation is very low in the isolated cells, it could
diminish or even vanish under suboptimal culture conditions. For all these reasons protocols need
to be ameliorated and standardized. In summary, current protocols and definitions for MSCs do
not entirely fulfil the requirements for a reliable use of MSCs in a clinical setting. In order to
41
approach this issues, it is compulsory to dissect the composition of MSCs on a single cell level
in order to get a better characterization of their heterogeneity. Previous studies carried out in
our research group have presented for instance that ASCs isolated with adapted protocols such
as stromal vascular fraction cells, which have no plastic adherence but ASC marker expression,
were likewise able to di↵erentiate towards osteoblasts and endothelial cells and were capable of
colonizing a three-dimensional electro spun nanocomposite of poly-lactic-co-glycolic acid [25].
The same study has shown that ASCs from di↵erent patients showed dissimilar competences in
their lineage propensity, although they were all capable of di↵erentiating into endothelial cells
and osteoblasts [25]. Furthermore, another study has presented that defined subpopulations of
stem and progenitor cells (NG2+, CD146+, CD45-) can be enriched and then directly applied as
a medical treatment without needing in vitro expansion [46]. Results from this study confirmed
the capacity of amplified NG2+, CD146+, CD45- cells not only to di↵erentiate e ciently towards
osteoblasts in vitro, but also to migrate into cancellous bone sca↵olds and thereby positively in-
fluence healing of large bone defects in vivo [46]. This study gave evidence that enriched cell
subpopulations with stem/progenitor character could be used directly for medical applications.
Moreover, the existence of cell subpopulations within ASCs and SVF with enhanced osteogenic
di↵erentiation potential was confirmed. This data implies that the variety of di↵erential poten-
tials in ASCs from di↵erent donors arises from the heterogeneous populations of ASCs rather
than a disturbance of their di↵erentiation ability. Our present hypothesis is that just a few
distinct subpopulations have an enhanced bone regeneration capacity. Thereby patients having
low quantity of these defined subpopulations may show impaired bone fracture healing for this
reason. Therefore, we decided to investigate this hypothesis by analysing 21 ASCs cell lines
obtained from di↵erent patients.
As anticipated, all of the 21 cell lines expressed the classical MSC markers in their undi↵er-
entiated state, nevertheless at varying levels (Fig. 4). Similarly, upon induction of osteogenic
di↵erentiation, the analysed cell lines showed very dissimilar potentials to di↵erentiate into os-
teoblasts, while they were isolated, expanded, and di↵erentiated in exactly the same way (Fig. 5).
Gene expression profiles from osteogenic di↵erentiated ASCs reflected a similar pattern (Fig. 6).
To sum up, analysing a higher quantity of cell lines again confirmed our hypothesis that a strong
heterogeneity between the cell lines exists and that subpopulations with enhanced osteogenic
potential are truly present.
Adipogenic di↵erentiation showed that the ASC lines were indeed able to di↵erentiate towards
adipocytes, but also in this lineage, their capacity varied widely between the cell lines (Fig. 7).
This heterogeneous nature was mirrored not only in the lipid staining but also in the gene
expression profiles from the di↵erentiating lines (Fig. 8). Some lines showed good di↵erentiation
abilities in both osteoblasts and adipocytes. Others showed good osteogenic, but bad adipogenic
di↵erentiation. With this data, no correlation could be established, as there was no obvious
trend visible comparing the 21 cell lines. This data clearly indicates that ASCs obtained from
individual patients possess di↵erent potentials and therefore belongs to the individual nature.
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As for the chondrogenic di↵erentiation, all ASC line were able to di↵erentiate towards chon-
droblasts, but obvious di↵erences such as observed in the osteogenic and adipogenic di↵erentia-
tion could not be detected (Fig. 9). In order to achieve a better characterization of this lineage,
the current protocol need further improvement. Therefore, further investigation is needed to
evidently see whether there are any di↵erences concerning this lineage or not.
Overall, our data confirmed the trilineage potential of our ASCs. In this Doctoral Thesis,
observation of a correlation between the three lineages in one individual patient could not be
determined clearly. Some patients had an enhanced potential for bone formation, but their
adipogenic di↵erentiation ability was low. On the contrary, some patients showed great di↵er-
entiation potential in both: Osteogenic and adipogenic di↵erentiation. Comparing all the data
from the di↵erentiations, no obvious correlation could be established.
The described data clearly confirmed that the composition of ASCs is truly heterogeneous.
Furthermore, it is to assume that not only subpopulations within ASCs with a higher ability for
bone formation exist, but also subpopulations with higher propensity towards adipocytes and
chondrocytes di↵erentiation may be present. This would also explain why the ASC lines behave
so di↵erently, as they probably consist of various subpopulations with dissimilar di↵erentiation
abilities.
In order to explore why substantial di↵erences in fracture healing courses are present among
di↵erent patients, further investigation is urgently needed. In this case, the identification, iso-
lation, and further characterization of subpopulations with enhanced osteogenic potential is of
great interest. Subsequently, protocols need to be established which allow an enrichment of these
specific subpopulations avoiding the necessity of prolonged in vitro cell cultivation. The final
objective would be to be able to extract the cells of interest and then directly transplant the
enriched subpopulations with enhanced osteogenic potential into critical size bone defects. In
order to approach this goal, it is compulsory to study the composition of ASCs on single cell
level.
Up to now, dissecting heterogeneous cell populations has been carried out with the widely
known method of fluorescence activated cell sorting (FACS). However, FACS has limitations
such as only having the capacity to detect a very small number of protein markers. In contrast,
the novel technology cytometry by time-of-flight (CyTOF) enables real-time analysis of single
cells and has theoretically over 120 detection channels using heavy metal isotopes for marker
distinction [47, 29]. This technology allows for the first time a broad characterization of highly
heterogeneous populations of cells as it enables functional and phenotypical cell profiling on a
single cell resolution. CyTOF has already been successfully used for hematopoietic stem cell
characterization ([47, 48]) but was never operated in order to characterize human ASCs. For the
very first time, in this Doctoral Thesis, we aimed at illuminating the multi-dimensional marker
distribution over the heterogeneous composition of ASCs at single cell level. Furthermore, our
goal was to dissect the heterogeneity of human ASCs in order to identify subpopulations of ASCs
responsible for osteogenic di↵erentiation. In future, these cells could be applied to ameliorate
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treatment procedures of critical size bone defects and as a consequence their clinical outcomes.
A tissue engineered approach with ASC subpopulations of enhanced osteogenic potential may
be more e cient and less invasive as the currently used standard methods.
For data acquisition with CyTOF, we used a previously established antibody panel including
not only classical MSC markers, but also other markers described in relation with MSCs/ASCs
(Tab. 3). Not only positive markers, but also defined negative markers were integrated in the
panel. Additionally, markers for osteogenic di↵erentiation were included in order to monitor the
osteogenic di↵erentiation progression over the four days of the experiment. With this setting, we
could for instance confirm that our ASC lines were truly bona fide MSCs fulfilling the criteria
from the ISCT.
In the primary part of the mass cytometry data analysis we made use of the first developed
computational tool for this kind of data, the t-SNE algorithm. This algorithm visualizes multi-
parametric data of single cells on a low dimensional map. The t-SNE cloud places related cells
closer to each other than unrelated ones. Overall, this algorithm allows visualization of CyTOF
data by dimensionality reduction in a two dimensional space by conserving the multidimension-
ality at single-cell resolution. Our data displayed that in the undi↵erentiated cells the classical
MSC markers CD73, CD105, and CD90 were located in a specific region (in the upper left side)
within the t-SNE cloud (Fig. 10). Interestingly, the tyrosine kinase receptors PDGFRa, EGFR
and also the pericyte marker NG2 seemed to be related to those cells being expressed from cells in
the same region of the cloud. Also osteogenic di↵erentiation marker RUNX2 displayed a similar
expression.
In order to characterize the ASC lines more accurately, an approach which enables identifi-
cation of rare cell subsets was needed. We therefore made use of a recently developed algorithm
called CellCnn [39]. The latter is able to detect rare cell subsets associated with a prior known
phenotype through representation learning by using a convolutional neural network [39]. We
first applied this algorithm to our data of the undi↵erentiated cells of all cell lines using the
outcome of the Alizarin red staining as the phenotype. In the analysis of our 20 ASC lines,
the endpoint was a good or bad ability for osteogenic di↵erentiation. CellCnn was trained to
identify cell subpopulations that di↵er in abundance between the good and the bad group. Two
subpopulations were identified, one that was more abundant in the good, and one that was more
abundant in the bad lines.
The identified subpopulation 1, which was found by CellCnn to be more abundant in the
bad lines, showed cells intensely expressing the classical MSC markers (Fig 11). In contrast,
subpopulation 2, which was more abundant in the good lines, displayed a lower amount of cells
expressing these classical markers (Fig. 12). Interestingly, osteogenic di↵erentiation marker AP
was highly expressed form a large amount of cells within this subpopulation 2 (Fig. 12). It
may be assumed that the cells from the bad lines remained in a kind of stem cell state, as they
expressed the MSC markers intensively. In contrast, the good lines seem to be more prone to
di↵erentiate into osteoblasts, which was mirrored in their high expression of AP as well as a low
44
expression of MSC markers.
Summarizing, already in the undi↵erentiated state of the ASCs, we were able to detect
di↵erences between the good and the bad osteogenic di↵erentiating lines. This was illustrated
through the two determined subpopulations varying in their frequency and expressing biomarkers
di↵erently compared in the good and bad lines (Fig. 11 and 12). These are very promising results,
since an immediate identification of the right cells of interest and their enrichment through, for
instance, a cell sorting technique could avoid prolonged in vitro culturing and could be applied
immediately for treatment purposes. Thus, clinical outcomes of critical size bone defects could
be significantly improved and bone regeneration accelerated.
Therefore, as a next step, our aim was to identify biomarkers, which would enable immediate
identification of ASCs with enhanced bone di↵erential potential. Thus, the time-consuming in
vitro culturing (with all the physiological changes related with the in vitro culture) could be
avoided and treatment could be instantaneously accomplished. Therefore, changes of expression
levels of selected markers were monitored over four days of osteogenic di↵erentiation. The MSC
marker CD73 seemed to be suitable for distinguishing between good and bad lines, as its median
expression value was generally remarkably lower in the good and intermediate lines in comparison
to the bad lines (Fig. 16B). Another interesting marker is AP, which showed a continuous
increase in the good and intermediate lines compared to the bad lines, where the abundance
stayed steadily on a low level (Fig. 16A). This data again confirmed the dissimilarity between
good and bad osteogenic di↵erentiating ASC lines. The heterogeneity, which could already be
seen in the undi↵erentiated cells at day zero, was in fact also reflected in the di↵erentiation
process. The classical MSC marker CD105 was also investigated over the time of osteogenic
di↵erentiation. In this marker, abundances did not di↵er in such a clearly manner than in the
other two scrutinized markers CD73 and AP (Fig. 16C). Therefore, this marker would be an
unsuitable marker for detection of the right set of cells.
With this preliminary staged data, even with an antibody panel containing only a limited
amount of markers, di↵erences between the ASC lines were still noticeable. Notwithstanding, a
further expansion of the antibody panel with more markers for undi↵erentiated, as well as for
cells di↵erentiating into osteoblasts is required. With this presented data, one can clearly see
that the ASC population is more complex than initially assumed. With the novel technology of
CyTOF, it is possible to expand the antibody panel to a large extent. A further approach would
be to isolate the specific population of cells (CD73 low and AP high) and to investigate only
these specific subpopulations.
It would also be interesting to implement markers in the antibody panel for the other two
mesenchymal lineages, fat and cartilage, and perform a similar analysis with mass cytometry as
for the osteogenic di↵erentiation. Exploring the same population, which was identified having
enhanced osteogenic potential would be of great interest as these cells might be capable of
di↵erentiating into the other two lineages. Another more likely hypothesis would be that di↵erent
subpopulations have a specific lineage propensity.
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In conclusion, the results presented above, even though still on a preliminary stage, project a
new vision for medical applications of ASCs. In order to achieve the possibility to directly implant
the cells of interest for medical treatment, it is compulsory to develop transplantation protocols
compatible with the clinics. In order to avoid in vitro expansion, cell sorting with specific markers
(CD73 low and AP high) for enrichment of the right cells would be an interesting strategy. This
procedure could be performed in parallel to the surgery of the fracture, and therefore, a second
surgery as currently needed in the standard treatment of critical size bone defects would not be
necessary. With this, quality of fracture repair and their subsequent clinical outcome could be
ameliorated significantly and be taken on whole new level. The identified subpopulation with a
higher abundance in the good osteogenic di↵erentiating ASC lines represents a very promising
approach for tissue engineering with ASCs in orthopaedic surgery.
5.2 Outlook
For this Doctoral Thesis, CyTOF analysis of ASCs was carried out with a relatively small
antibody panel including only positive and negative stem cell markers as well as two osteogenic
markers. Based on the data obtained, the composition of subpopulations in ASCs seems to be
more complex than initially presumed. Therefore, the analysis procedure needs optimization in
order to better understand the ASC composition of subpopulations. Following investigations
need to be carried out for further dissection of the heterogeneity of ASCs:
• Expansion of the established antibody panel for mass cytometry. Inclusion of more markers
not only for osteogenic, but also for adipogenic and chondrogenic di↵erentiation. A new
antibody of interest requires conjugation to an appropriate heavy metal and titration on
both negative and positive control cells.
• Identification of new markers through transcriptomic analysis.
• In case of unavailability of specific antibodies, mRNAs can be conjugated to heavy metals.
This novel approach enables specific selection of mRNAs against a markers of interest [49].
• Investigation of osteogenic di↵erentiation with mass cytometry over a longer period of
time than four days. Due to the increasing calcium deposition, trypsinisation of the di↵er-
entiating cells became more challenging the longer the di↵erentiation was carried out. A
recently developed approach named imaging mass cytometry could be a possible solution
for this issue [50]. With this method, osteogenic di↵erentiating cells can be left in their cell
culture dishes for analysis and therefore be di↵erentiated for a longer period of time.
• In order to obtain an exhaustive informative panel of the 20 analysed ASC lines, it would
be particularly interesting to perform a CyTOF analysis with these cell lines di↵erentiat-
ing into adipocytes and chondroblasts in a similar way than described for the osteogenic
di↵erentiation in this Doctoral Thesis.
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• The ultimate aim of the whole project would be to isolate the subpopulations with a higher
osteogenic di↵erentiation ability and their evaluation on a murine femur fracture model.
• Another interesting research topic would be the comparison of ASCs extracted not only
from healthy patients, but also from patients su↵ering from osteoporosis.
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